Labcorp Holdings Inc. $LH Shares Bought by Lansforsakringar Fondforvaltning AB publ

Lansforsakringar Fondforvaltning AB publ lifted its stake in shares of Labcorp Holdings Inc. (NYSE:LH) by 13.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,745 shares of the medical research company’s stock after purchasing an additional 3,395 shares during the period. Lansforsakringar Fondforvaltning AB publ’s holdings in Labcorp were worth $7,964,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in LH. SP Asset Management LLC lifted its position in Labcorp by 0.3% during the second quarter. SP Asset Management LLC now owns 14,177 shares of the medical research company’s stock worth $3,722,000 after buying an additional 38 shares in the last quarter. HBK Sorce Advisory LLC increased its stake in shares of Labcorp by 4.3% in the 3rd quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company’s stock worth $254,000 after acquiring an additional 38 shares during the last quarter. Pure Financial Advisors LLC raised its holdings in shares of Labcorp by 3.9% during the 3rd quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company’s stock worth $292,000 after acquiring an additional 38 shares during the period. Zions Bancorporation National Association UT boosted its position in shares of Labcorp by 21.9% during the 2nd quarter. Zions Bancorporation National Association UT now owns 223 shares of the medical research company’s stock valued at $59,000 after acquiring an additional 40 shares during the last quarter. Finally, Hantz Financial Services Inc. grew its holdings in shares of Labcorp by 48.8% in the third quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 40 shares during the period. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on LH. Weiss Ratings raised shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. Morgan Stanley restated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Robert W. Baird upped their price objective on Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. UBS Group lowered their price objective on Labcorp from $325.00 to $320.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. Finally, Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Labcorp currently has an average rating of “Moderate Buy” and a consensus target price of $302.75.

Labcorp Stock Performance

Shares of LH stock opened at $285.15 on Tuesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. The firm has a market cap of $23.64 billion, a P/E ratio of 27.26, a P/E/G ratio of 1.93 and a beta of 1.03. The firm’s 50 day moving average price is $265.93 and its 200-day moving average price is $269.49. Labcorp Holdings Inc. has a one year low of $209.38 and a one year high of $293.72.

Labcorp (NYSE:LH) last announced its earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The company had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. During the same quarter in the previous year, the company earned $3.45 earnings per share. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, equities research analysts predict that Labcorp Holdings Inc. will post 16.01 EPS for the current year.

Labcorp Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Friday, February 27th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Friday, February 27th. Labcorp’s payout ratio is currently 27.53%.

Insider Activity

In other news, CEO Adam H. Schechter sold 5,273 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $284.38, for a total value of $1,499,535.74. Following the completion of the transaction, the chief executive officer owned 87,343 shares of the company’s stock, valued at approximately $24,838,602.34. This trade represents a 5.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Jonathan C. Meltzer sold 87 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $290.42, for a total transaction of $25,266.54. Following the sale, the executive vice president directly owned 2,782 shares in the company, valued at approximately $807,948.44. The trade was a 3.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.84% of the company’s stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.